|
|
Maternal mediators of fetal growth restriction linked to prenatal alcohol exposure |
| 1R01AA029594-01A1 |
|
NIAAA |
2022 |
|
|
Cardiovascular disease in fetal alcohol spectrum disorder |
| 1U01AA030185-01 |
|
NIAAA |
2022 |
|
|
Project 2: Prenatal Alcohol Exposure (PAE) and Fetal Alcohol Spectrum Disorder (FASD) |
| 1U54AA030451-01 |
|
NIAAA |
2022 |
|
|
Prenatal Alcohol Exposure and Fetal Alcohol Spectrum Disorder |
| 1U54AA030463-01 |
|
NIAAA |
2022 |
|
|
Prenatal Alcohol and Neuroimmunity |
| 5R01AA022460-08 |
|
NIAAA |
2022 |
|
|
Fetal alcohol exposure: effects on immunity of the premature newborn |
| 5R01AA027020-04 |
|
NIAAA |
2022 |
|
|
Implant Biofilm Mediated Immune Response |
| 1R01AI165958-01A1 |
|
NIAID |
2022 |
|
|
Monitoring Treatment Efficacy in Leprosy |
| 1R21AI171254-01 |
|
NIAID |
2022 |
|
|
Novel Biofilm Paradigm Explaining Clinical Implant-Associated Illness. |
| 1R21AI171932-01 |
|
NIAID |
2022 |
|
|
Nanoimmunotherapy for chronic immune-mediated diseases |
| 1R41AI170413-01 |
|
NIAID |
2022 |